Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
Updated Oct. 23, 2023 6:55 am ETRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant...
Biopharmaceuticals
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
The deal expands the pharmaceutical company’s portfolio of cancer drugs. Source link
Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle
The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact...
FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics
The move gives the agency time to weigh a settlement that would allow the deal to close with conditions. Source...
Biogen Buying Rare-Disease Drugmaker in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link
FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
ShareListen(2 min) Source link
U.S. Appeals Court Sides With Drugmakers on Discount Program
BusinessHealth CareHealthDrugmakers can limit shipments to hospitals and clinics of drugs discounted under federal program, court rules in loss for...
Amgen Agrees to Deal to Buy Horizon Therapeutics
BusinessThe U.S. biotechnology company will pay $116.50 for each Horizon share Source link
Pfizer, Uber and Starbucks Highlight Another Busy Earnings Week
Pfizer Inc., PFE 3.69% Uber UBER -1.15% Technologies Inc. and Starbucks Corp. SBUX 2.13% are among the heavyweights headlining another...
Pfizer’s New Omicron-Targeting Booster Produces Strong Immune Response
The retooled Covid-19 booster from Pfizer Inc. and BioNTech SE generated a strong immune response against the Omicron substrains BA.4...
Covid-19 Booster Shots Targeting Omicron Authorized, Likely to Be Offered Soon
U.S. health regulators cleared use of retooled Covid-19 vaccines that target the latest versions of Omicron, in preparation for a...
Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics
Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the...
WSJ News Exclusive | Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer Inc. PFE -1.18% is in advanced talks to buy Global Blood Therapeutics Inc., GBT 33.03% the maker of a...
Starbucks, Uber, CVS to Report Earnings Amid Shrinking Economy
About 30% of S&P 500 companies are slated to report earnings in the coming week, according to FactSet. Two Dow...
CDC Recommends Novavax’s Covid Vaccine for Adults 18 and Older
The Centers for Disease Control and Prevention on Tuesday recommended the use of Novavax Inc.’s Covid-19 vaccine, the final hurdle...
WSJ News Exclusive | Merck Deal for Seagen Seen as Unlikely by Earnings Release
Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s...
Pfizer’s Omicron-Targeting Covid-19 Vaccines Generate Stronger Immune Response
Pfizer Inc. and BioNTech SE vaccines modified to target the Omicron variant produced a significantly larger immune response than the...
WSJ News Exclusive | Merck Explores Purchase of Biotech Seagen
Merck MRK -0.32% & Co. is eyeing a purchase of biotech Seagen Inc., SGEN 12.72% according to people familiar with...
FDA Advisers Review Pfizer, Moderna Covid-19 Vaccines in Young Children
A positive recommendation would likely lead soon to expanding the U.S. Covid-19 vaccination campaign to the 19.6 million children 6...
Three-Dose Pfizer Covid Vaccine Works Safely in Young Children, Review Says
The FDA staff also said, in a review of study data posted online Sunday, that there were no new safety...
